Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel Free UMRX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Cogent Biosciences (UMRX) Competitors

Cogent Biosciences logo
Compare

UMRX vs. MANE, KLRA, GMTX, MOR, and ZYME

Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include MANE (MANE), Kailera Therapeutics (KLRA), Gemini Therapeutics (GMTX), MorphoSys (MOR), and Zymeworks (ZYME).

How does Cogent Biosciences compare to MANE?

MANE (NYSE:MANE) and Cogent Biosciences (NASDAQ:UMRX) are both pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

26.4% of Cogent Biosciences shares are held by institutional investors. 31.5% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, MANE had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for MANE and 0 mentions for Cogent Biosciences. MANE's average media sentiment score of 0.92 beat Cogent Biosciences' score of 0.00 indicating that MANE is being referred to more favorably in the media.

Company Overall Sentiment
MANE Positive
Cogent Biosciences Neutral

MANE presently has a consensus price target of $83.33, indicating a potential downside of 27.27%. Given MANE's stronger consensus rating and higher possible upside, equities analysts clearly believe MANE is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MANE
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Cogent Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

MANE has higher earnings, but lower revenue than Cogent Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MANEN/AN/AN/AN/AN/A
Cogent Biosciences$22.50M69.74-$31.83M-$1.04N/A

MANE has a net margin of 0.00% compared to Cogent Biosciences' net margin of -96.84%. MANE's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MANEN/A N/A N/A
Cogent Biosciences -96.84%-87.78%-52.14%

Summary

MANE beats Cogent Biosciences on 8 of the 11 factors compared between the two stocks.

How does Cogent Biosciences compare to Kailera Therapeutics?

Cogent Biosciences (NASDAQ:UMRX) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Kailera Therapeutics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 1 mentions for Kailera Therapeutics and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.00 equaled Kailera Therapeutics'average media sentiment score.

Company Overall Sentiment
Cogent Biosciences Neutral
Kailera Therapeutics Neutral

26.4% of Cogent Biosciences shares are held by institutional investors. 31.5% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kailera Therapeutics has lower revenue, but higher earnings than Cogent Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cogent Biosciences$22.50M69.74-$31.83M-$1.04N/A
Kailera TherapeuticsN/AN/AN/AN/AN/A

Kailera Therapeutics has a net margin of 0.00% compared to Cogent Biosciences' net margin of -96.84%. Kailera Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cogent Biosciences-96.84% -87.78% -52.14%
Kailera Therapeutics N/A N/A N/A

Summary

Kailera Therapeutics beats Cogent Biosciences on 4 of the 7 factors compared between the two stocks.

How does Cogent Biosciences compare to Gemini Therapeutics?

Cogent Biosciences (NASDAQ:UMRX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Gemini Therapeutics has a net margin of 0.00% compared to Cogent Biosciences' net margin of -96.84%. Gemini Therapeutics' return on equity of -38.78% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cogent Biosciences-96.84% -87.78% -52.14%
Gemini Therapeutics N/A -38.78%-35.88%

In the previous week, Gemini Therapeutics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company Overall Sentiment
Cogent Biosciences Neutral
Gemini Therapeutics Neutral

Cogent Biosciences has a beta of 3.93, meaning that its stock price is 293% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.

Cogent Biosciences has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cogent Biosciences$22.50M69.74-$31.83M-$1.04N/A
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A

26.4% of Cogent Biosciences shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 31.5% of Cogent Biosciences shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Gemini Therapeutics beats Cogent Biosciences on 6 of the 11 factors compared between the two stocks.

How does Cogent Biosciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Cogent Biosciences (NASDAQ:UMRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Cogent Biosciences'average media sentiment score.

Company Overall Sentiment
MorphoSys Neutral
Cogent Biosciences Neutral

Cogent Biosciences has lower revenue, but higher earnings than MorphoSys. Cogent Biosciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Cogent Biosciences$22.50M69.74-$31.83M-$1.04N/A

Cogent Biosciences has a net margin of -96.84% compared to MorphoSys' net margin of -226.79%. Cogent Biosciences' return on equity of -87.78% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Cogent Biosciences -96.84%-87.78%-52.14%

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 31.5% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500.

Summary

Cogent Biosciences beats MorphoSys on 8 of the 11 factors compared between the two stocks.

How does Cogent Biosciences compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Zymeworks has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500.

In the previous week, Zymeworks had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Cogent Biosciences. Zymeworks' average media sentiment score of 0.45 beat Cogent Biosciences' score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.

Company Overall Sentiment
Zymeworks Neutral
Cogent Biosciences Neutral

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 31.5% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zymeworks has a net margin of -76.56% compared to Cogent Biosciences' net margin of -96.84%. Zymeworks' return on equity of -26.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Zymeworks-76.56% -26.00% -20.57%
Cogent Biosciences -96.84%-87.78%-52.14%

Zymeworks currently has a consensus price target of $37.89, indicating a potential upside of 42.01%. Given Zymeworks' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zymeworks is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92
Cogent Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cogent Biosciences has lower revenue, but higher earnings than Zymeworks. Cogent Biosciences is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$105.96M18.57-$81.13M-$1.08N/A
Cogent Biosciences$22.50M69.74-$31.83M-$1.04N/A

Summary

Zymeworks beats Cogent Biosciences on 13 of the 17 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UMRX vs. The Competition

Export
MetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$1.57B$886.55M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E Ratio-48.621.7129.2527.07
Price / Sales69.74120.63504.6873.47
Price / CashN/A20.0743.3053.90
Price / Book35.537.609.676.69
Net Income-$31.83M-$4.80M$3.55B$332.64M

Cogent Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UMRX
Cogent Biosciences
N/A$36.95
+3.7%		N/AN/A$1.57B$22.50MN/A72
MANE
MANE
N/A$101.83
-4.4%		$83.33
-18.2%		N/A$3.80BN/AN/A19
KLRA
Kailera Therapeutics
N/A$24.73
-0.1%		N/AN/A$3.06BN/AN/A145
GMTX
Gemini Therapeutics
N/A$67.26
-2.3%		N/AN/A$2.91BN/AN/A30
MOR
MorphoSys
N/A$18.96
flat		N/AN/A$2.86B$238.28MN/A730

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UMRX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel